FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Stefan Holdenrieder

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Yvonne Nadine Fahmueller; Ralf-Thorsten Hoffmann; Tobias Jakobs; Dorothea Nagel; Petra Stieber; Klaus Tatsch; Stefan Holdenrieder
Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.
Stefan Boeck; M Haas; Volker Heinemann; C Kern; Dorothea Nagel; Petra Stieber; C Wittwer; Stefan Holdenrieder
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Michael Haas; Volker Heinemann; Stefan Holdenrieder; Christina Klose; Frank Kullmann; Rüdiger P Laubender; Dominik P Modest; Christoph Schulz; Christiane J Bruns; Stefan Boeck
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Stefan Holdenrieder (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Yvonne Nadine Fahmueller; Ralf-Thorsten Hoffmann; Tobias Jakobs; Dorothea Nagel; Petra Stieber; Klaus Tatsch; Stefan Holdenrieder
Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.
International journal of cancer. Journal international du cancer 2013;132(10):2349-58.
2013: Stefan Boeck; M Haas; Volker Heinemann; C Kern; Dorothea Nagel; Petra Stieber; C Wittwer; Stefan Holdenrieder
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
British journal of cancer 2013;108(8):1684-94.
2013: Michael Haas; Volker Heinemann; Stefan Holdenrieder; Christina Klose; Frank Kullmann; Rüdiger P Laubender; Dominik P Modest; Christoph Schulz; Christiane J Bruns; Stefan Boeck
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
Journal of cancer research and clinical oncology 2013;139(4):681-9.
2013: Ugur Gezer; Neslihan Abaci; Aris Cakiris; Nejat Dalay; Gloria Leszinski; Duran ustek; Ebru E Yörüker; Stefan Holdenrieder
Characterization of H3K9me3- and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2013;34(1):329-36.
2013: Oliver J Stoetzer; Michael Braun; Axel-Mario Feller; Debora M I Fersching; Christian J Gabka; Ulrich Hamann; Volker Heinemann; Dorothea Nagel; Christoph Salat; Barbara Siegele; Oliver Steinkohl; Stefan Holdenrieder
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2013;34(1):81-90.
2013: Katharina Zeiss; Michael Haas; Volker Heinemann; Stefan Holdenrieder; Rüdiger P Laubender; Klaus G Parhofer; Christoph Schulz; Stefan Boeck
Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy.
Anticancer research 2013;33(1):287-92.
2013: Nikolaus Kohles; Dorothea Nagel; Petra Stieber; Dietrich Jüngst; Stefan Holdenrieder
DNase is a prognostic marker in liver cancer patients receiving transarterial chemoembolization therapy.
International journal of clinical pharmacology and therapeutics 2013;51(1):80-3.
2013: Christin Wittwer; Dorothea Nagel; Petra Stieber; Stefan Boeck; Michael Haas; Volker Heinemann; Stefan Holdenrieder
Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients.
International journal of clinical pharmacology and therapeutics 2013;51(1):67-9.
2013: Yvonne Nadine Fahmueller; Ralf-Thorsten Hoffmann; Tobias Jakobs; Dorothea Nagel; Petra Stieber; Klaus Tatsch; Stefan Holdenrieder
CA 15-3 is a predictive and prognostic biomarker in patients with metastasized breast cancer undergoing Selective Internal Radiation Therapy.
International journal of clinical pharmacology and therapeutics 2013;51(1):63-6.
2013: Julia Lehner; Dorothea Nagel; Oliver J Stötzer; Debora M I Fersching; Stefan Holdenrieder
Plasma DNA integrity indicates response to neoadjuvant chemotherapy in patients with locally confined breast cancer.
International journal of clinical pharmacology and therapeutics 2013;51(1):59-62.
2012: Nikolaus Kohles; Dorothea Nagel; Petra Stieber; Dietrich Jüngst; Stefan Holdenrieder
Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2012;33(6):2401-9.
2012: Imke Sanders; Alexander von Ruecker; Gisela Walgenbach-Brünagel; Stefan Holdenrieder; Glen Kristiansen; Stefan C Müller; Jörg Ellinger
Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma.
International journal of urology : official journal of the Japanese Urological Association 2012;19(11):1017-25.
2012: Stefan Hauser; Edwin Herrmann; Stefan Holdenrieder; Volker Jung; Rudolf Moritz; Stefan C Müller; Carsten-Henning Ohlmann; Alexander von Ruecker; Gisela Walgenbach-Brünagel; Lena M Wulfken; Frank Becker; Jörg Ellinger
Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma.
Cancer epidemiology 2012;36(4):391-4.
2012: Oliver J Stoetzer; Christin Wittwer; Yvonne N Fahmueller; Debora M I Fersching; Nikolaus Kohles; Julia Lehner; Gloria Leszinski; Juliane Roessner; Stefan Holdenrieder
Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy.
Expert opinion on biological therapy 2012;12 Suppl 1():S217-24.
2012: Gloria Leszinski; Barbara Siegele; Oliver J Stoetzer; Ugur Gezer; Stefan Holdenrieder
Relevance of histone marks H3K9me3 and H4K20me3 in cancer.
Anticancer research 2012;32(5):2199-205.
2012: Stefan Holdenrieder; Frank T Kolligs; Davit Manukyan; Jan Braess; Petra Stieber
Nature and dynamics of nucleosome release from neoplastic and non-neoplastic cells.
Anticancer research 2012;32(5):2179-83.
2012: Christin Wittwer; Debora Fersching; Julia Lehner; Barbara Siegele; Oliver J Stoetzer; Stefan Holdenrieder
Methodological and preanalytical evaluation of a RAGE immunoassay.
Anticancer research 2012;32(5):2075-8.
2012: Julia Lehner; Barbara Siegele; Debora Fersching; Stefan Holdenrieder; Christin Wittwer; Oliver J Stoetzer
Methodological and preanalytical evaluation of an HMGB1 immunoassay.
Anticancer research 2012;32(5):2059-62.
2012: Debora M I Fersching; Volker Heinemann; Stefan Holdenrieder; Dorothea Nagel; Christoph Salat; Barbara Siegele; Oliver J Stoetzer
Apoptosis-related biomarkers sFAS, MIF, ICAM-1 and PAI-1 in serum of breast cancer patients undergoing neoadjuvant chemotherapy.
Anticancer research 2012;32(5):2047-58.
2012: Stefan Holdenrieder; J Dreslerova; Jindrich Finek; Vaclav Liska; V M Matejka; Petra Stieber; Ondrej Topolcan; V Treska; Lubos Holubec
Cytokeratin serum biomarkers in patients with colorectal cancer.
Anticancer research 2012;32(5):1971-6.
2012: Berndt Zur; Gisela Walgenbach-Brünagel; Eike Albers; Stefan Holdenrieder; Birgit Stoffel-Wagner
Method comparison for CA 15-3, CA 19-9, and CA 125 determination using the new LOCI technique of Dimension Vista 1500 and Immulite 2000 XPI.
Journal of immunoassay & immunochemistry 2012;33(4):435-45.
2012: Berndt Zur; Gisela Walgenbach-Brünagel; Eike Albers; Stefan Holdenrieder; Birgit Stoffel-Wagner
Method comparison for determination of the tumor markers AFP, CEA, PSA and free PSA between Immulite 2000 XPI and Dimension Vista 1500.
Clinical laboratory 2012;58(1-2):97-105.
2012: Yvonne Nadine Fahmueller; Ralf-Thorsten Hoffmann; Tobias Jakobs; Dorothea Nagel; Petra Stieber; Klaus Tatsch; Stefan Holdenrieder
Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy.
BMC cancer 2012;12():5.
2011: Michael Fleischhacker; Debora M I Fersching; Gloria S Leszinski; Dorothea Nagel; Bernd Schmidt; Barbara Siegele; Oliver J Stötzer; Sabine Weickmann; Stefan Holdenrieder
Methods for isolation of cell-free plasma DNA strongly affect DNA yield.
Clinica chimica acta; international journal of clinical chemistry 2011;412(23-24):2085-8.
2011: Berndt Zur; Stefan Holdenrieder; Markus Look; Birgit Stoffel-Wagner
Elevated plasma myeloperoxidase concentration in adults with obesity.
Clinica chimica acta; international journal of clinical chemistry 2011;412(19-20):1891-2.
2011: Fulya Yaman Agaoglu; Müge Kovancilar; Yavuz Dizdar; Emin Darendeliler; Stefan Holdenrieder; Nejat Dalay; Ugur Gezer
Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2011;32(3):583-8.
2011: Lena M Wulfken; Frank Becker; Edwin Herrmann; Stefan Holdenrieder; Volker Jung; Rudolf Moritz; Stefan C Müller; Carsten Ohlmann; Alexander von Ruecker; Gisela Walgenbach-Brünagel; Jörg Ellinger
MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels.
PloS one 2011;6(9):e25787.
2011: Nikolaus Kohles; Dorothea Nagel; Petra Stieber; Jürgen Durner; Dietrich Jüngst; Stefan Holdenrieder
Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients.
BMC cancer 2011;11():202.
2010: Ugur Deligezer; Fulya Yaman; Emin Darendeliler; Yavuz Dizdar; Stefan Holdenrieder; Müge Kovancilar; Nejat Dalay
Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.
Clinica chimica acta; international journal of clinical chemistry 2010;411(19-20):1452-6.
2010: Steffen Massberg; Lenka Grahl; Marie-Luise von Bruehl; Davit Manukyan; Susanne Pfeiler; Christian Goosmann; Volker Brinkmann; Michael Lorenz; Kiril Bidzhekov; Avinash B Khandagale; Ildiko Konrad; Elisabeth Kennerknecht; Katja Reges; Stefan Holdenrieder; Siegmund Braun; Christoph Reinhardt; Michael Spannagl; Klaus T Preissner; Bernd Engelmann
Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases.
Nature medicine 2010;16(8):887-96.
2010: Michael Haas; Rüdiger P Laubender; Petra Stieber; Stefan Holdenrieder; Christiane J Bruns; Ralf Wilkowski; Ulrich Mansmann; Volker Heinemann; Stefan Boeck
Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2010;31(4):351-7.
2010: Stefan Holdenrieder; Joachim von Pawel; Thomas Duell; Knut Feldmann; Hannelore Raith; Annette Schollen; Dorothea Nagel; Petra Stieber
Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Anticancer research 2010;30(5):1855-62.
2010: Stefan Holdenrieder; Joachim von Pawel; Dorothea Nagel; Petra Stieber
Long-term stability of circulating nucleosomes in serum.
Anticancer research 2010;30(5):1613-5.
2010: Stefan Boeck; Michael Haas; Rüdiger P Laubender; Frank Kullmann; Christina Klose; Christiane J Bruns; Ralf Wilkowski; Petra Stieber; Stefan Holdenrieder; Hannes Buchner; Ulrich Mansmann; Volker Heinemann
Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(3):986-94.
2010: Petra Stieber; Stefan Holdenrieder
Lung cancer biomarkers - Where we are and what we need.
Cancer biomarkers : section A of Disease markers 2010;6(3-4):221-4.
2010: Stefan Holdenrieder; Petra Stieber
Circulating apoptotic markers in the management of non-small cell lung cancer.
Cancer biomarkers : section A of Disease markers 2010;6(3-4):197-210.
2010: Vivian Barak; Stefan Holdenrieder; Benjamin Nisman; Petra Stieber
Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer.
Cancer biomarkers : section A of Disease markers 2010;6(3-4):191-6.
2010: Stefan Holdenrieder; Dorothea Nagel; Petra Stieber
Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer.
Cancer biomarkers : section A of Disease markers 2010;6(3-4):179-90.
2010: Rafael Molina; Stefan Holdenrieder; Jose Maria Auge; Andreas Schalhorn; Rudolf A. Hatz; Petra Stieber
Diagnostic relevance of circulating biomarkers in patients with lung cancer.
Cancer biomarkers : section A of Disease markers 2010;6(3-4):163-78.
2010: Stefan Holdenrieder; Petra Stieber
New challenges for laboratory diagnostics in non-small cell lung cancer.
Cancer biomarkers : section A of Disease markers 2010;6(3-4):119-21.
2009: Andreas E. Kremer; Christian Rust; Peter Eichhorn; Ulrich Beuers; Stefan Holdenrieder
Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers.
Expert review of molecular diagnostics 2009;9(2):139-56.
2009: Thomas Bertsch; Christine Aschenneller; Verena Herzog; Anne Marie Dupuy; Anne Sophie Bargnoux; Stephanie Badiou; Anne Ebel; Angela Winter; Adeltraud Graf; Stefan Rauch; Jürgen Durner; Stefan Holdenrieder; Peter Fraunberger; Raymond Gamble; Brian Sheridan; Janine Kukula; Paul Kenny; Jean Paul Cristol
A multicenter assessment of the analytical performance of the routine thyroid panel on the Olympus AU3000i immunoassay system.
Clinical laboratory 2009;55(11-12):447-58.
2008: Stefan Holdenrieder; Joachim von Pawel; Elke Dankelmann; Thomas Duell; Bernhard Faderl; Andreas Markus; Maria Siakavara; Horst Wagner; Knut Feldmann; Harald Hoffmann; Hannelore Raith; Dorothea Nagel; Petra Stieber
Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7813-21.
2008: Stefan Holdenrieder; Dorothea Nagel; Andreas Schalhorn; Volker Heinemann; Ralf Wilkowski; Joachim von Pawel; Hannelore Raith; Knut Feldmann; Andreas E. Kremer; Susanne Müller; Sandra Geiger; Gerhard F Hamann; Dietrich Seidel; Petra Stieber
Clinical relevance of circulating nucleosomes in cancer.
Annals of the New York Academy of Sciences 2008;1137():180-9.
2008: Stefan Holdenrieder; Alexander Burges; Oliver Reich; Fritz W Spelsberg; Petra Stieber
DNA integrity in plasma and serum of patients with malignant and benign diseases.
Annals of the New York Academy of Sciences 2008;1137():162-70.
2008: Stefan Holdenrieder; Frank T Kolligs; Petra Stieber
New horizons for diagnostic applications of circulating nucleosomes in blood?
Clinical chemistry 2008;54(7):1104-6.
2008: Rafael Molina; Massimo Gion; Axel Gressner; Frédéric Troalen; Jose Maria Auge; Stefan Holdenrieder; Matelda Zancan; Matthias Wycislo; Petra Stieber
Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(5):612-22.
2008: Petra Stieber; Rafael Molina; Massimo Gion; Axel Gressner; Frédéric Troalen; Stefan Holdenrieder; Jose Maria Auge; Matelda Zancan; Matthias Wycislo; Véronique Jarrige
Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access GI Monitor assay on the UniCel Dxl 800 Immunoassay System.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(5):600-11.
2008: Stefan Holdenrieder; Rafael Molina; Massimo Gion; Axel Gressner; Frédéric Troalen; Jose Maria Auge; Matelda Zancan; Matthias Wycislo; Petra Stieber
Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access OV Monitor assay on the UniCel Dxl 800 Immunoassay System.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(5):588-99.
2008: Helmut R Salih; Stefan Holdenrieder; Alexander Steinle
Soluble NKG2D ligands: prevalence, release, and functional impact.
Frontiers in bioscience : a journal and virtual library 2008;13():3448-56.
2007: Stefan Holdenrieder; Peter Eichhorn; Ulrich Beuers; Walter Samtleben; Petra Stieber; Dorothea Nagel; Andrea Peterfi; Alexander Steinle; Helmut R Salih
Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism.
Anticancer research 2007;27(4A):2041-5.
2007: Sandra Geiger; Stefan Holdenrieder; Petra Stieber; Gerhard F Hamann; Roland Brüning; Jun Ma; Dorothea Nagel; Dietrich Seidel
Nucleosomes as a new prognostic marker in early cerebral stroke.
Journal of neurology 2007;254(5):617-23.
2007: Stefan Boeck; Christoph Schulz; Petra Stieber; Stefan Holdenrieder; Sabine Weckbach; Volker Heinemann
Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy?
Onkologie 2007;30(1-2):39-42.
2006: Stefan Holdenrieder; Petra Stieber; Andrea Peterfi; Dorothea Nagel; Alexander Steinle; Helmut R Salih
Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA.
Cancer immunology, immunotherapy : CII 2006;55(12):1584-9.
2006: Stefan Holdenrieder; Peter Eichhorn; Ulrich Beuers; Walter Samtleben; Ulf Schönermarck; Reinhart Zachoval; Dorothea Nagel; Petra Stieber
Nucleosomal DNA fragments in autoimmune diseases.
Annals of the New York Academy of Sciences 2006;1075():318-27.
2006: Stefan Holdenrieder; Petra Stieber; Joachim von Pawel; Hannelore Raith; Dorothea Nagel; Knut Feldmann; Dietrich Seidel
Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments.
Annals of the New York Academy of Sciences 2006;1075():244-57.
2006: Stefan Holdenrieder; Petra Stieber; Andrea Peterfi; Dorothea Nagel; Alexander Steinle; Helmut R Salih
Soluble MICA in malignant diseases.
International journal of cancer. Journal international du cancer 2006;118(3):684-7.
2006: Stefan Boeck; Petra Stieber; Stefan Holdenrieder; Ralf Wilkowski; Volker Heinemann
Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer.
Oncology 2006;70(4):255-64.
2006: Andreas E. Kremer; Stefan Holdenrieder; Petra Stieber; Ralf Wilkowski; Dorothea Nagel; Dietrich Seidel
Nucleosomes in colorectal cancer patients during radiochemotherapy.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2006;27(5):235-42.
2006: Susanne Mueller; Stefan Holdenrieder; Petra Stieber; Torsten Haferlach; Andreas Schalhorn; Jan Braess; Dorothea Nagel; Dietrich Seidel
Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments.
BMC cancer 2006;6():143.
2006: Sandra Geiger; Stefan Holdenrieder; Petra Stieber; Gerhard F Hamann; Roland Brüning; Jun Ma; Dorothea Nagel; Dietrich Seidel
Nucleosomes in serum of patients with early cerebral stroke.
Cerebrovascular diseases (Basel, Switzerland) 2006;21(1-2):32-7.
2005: Stefan Holdenrieder; Petra Stieber; Lisa Y S Chan; Sandra Geiger; Andreas E. Kremer; Dorothea Nagel; Y M Dennis Lo
Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR.
Clinical chemistry 2005;51(8):1544-6.
2005: Stefan Holdenrieder; Susanne Mueller; Petra Stieber
Stability of nucleosomal DNA fragments in serum.
Clinical chemistry 2005;51(6):1026-9.
2005: Jindrich Finek; Lubos Holubec; Ondrej Topolcan; J Salvet; Richard Pikner; Stefan Holdenrieder; Petra Stieber; Rolf Lamerz; L Holubec Sen; Sarka Svobodova; Vladimir Visokai; E Helmichova
Clinical relevance of tumor markers for the control of chemotherapy.
Anticancer research 2005;25(3A):1655-8.
2005: Ondrej Topolcan; Lubos Holubec; Jindrich Finek; Petra Stieber; Stefan Holdenrieder; Rolf Lamerz; L Holubec Sen; Sarka Svobodova; Vladimir Visokai; Ludmila Lipska
Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy.
Anticancer research 2005;25(3A):1831-3.
2005: Stefan Holdenrieder; Lubos Holubec; Ondrej Topolcan; Jindrich Finek; Petra Stieber
Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapy.
Anticancer research 2005;25(3A):1795-801.
2005: Lubos Holubec; Ondrej Topolcan; Jindrich Finek; Stefan Holdenrieder; Petra Stieber; Martin Pesta; Richard Pikner; L Holubec Sen; Alan Sutnar; Vaclav Liska; Sarka Svobodova; Vladimir Visokai; Stanislav Kormunda
Markers of cellular adhesion in diagnosis and therapy control of colorectal carcinoma.
Anticancer research 2005;25(3A):1597-601.
2005: Andreas E. Kremer; Ralf Wilkowski; Stefan Holdenrieder; Dorothea Nagel; Petra Stieber; Dietrich Seidel
Nucleosomes in pancreatic cancer patients during radiochemotherapy.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2005;26(1):44-9.
2004: Stefan Holdenrieder; Dieter Lütjohann; Sandra Geiger; Klaus Von Bergmann; Petra Stieber; Gerhard F Hamann
Does brain specific 24S-hydroxycholesterol in plasma indicate the disruption of the blood-brain barrier in patients with ischemic stroke?
Neuroscience letters 2004;368(2):201-4.
2004: Stefan Holdenrieder; Petra Stieber; Joachim von Pawel; Hannelore Raith; Dorothea Nagel; Knut Feldmann; Dietrich Seidel
Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):5981-7.
2004: Stefan Holdenrieder; Jutta Stief; Albrecht Bergner; Fernando Gamarra; Anke Mitlewski; Dorothea Nagel; Rudolph M Huber; Petra Stieber
Nucleosomes indicate the in vitro radiosensitivity of irradiated bronchoepithelial and lung cancer cells.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2004;25(5-6):321-6.
2004: Stefan Holdenrieder; Petra Stieber
Apoptotic markers in cancer.
Clinical biochemistry 2004;37(7):605-17.
2004: Stefan Holdenrieder; Petra Stieber
Therapy control in oncology by circulating nucleosomes.
Annals of the New York Academy of Sciences 2004;1022():211-6.
2003: Albrecht Bergner; Jutta Stief; Stefan Holdenrieder; Petra Stieber; Wolfgang Haimerl; B Passlick; A Waldschmidt; JC Kummermehr; Fernando Gamarra; Rudolf Maria Huber
Effects of single-dose irradiation on bronchial epithelium: a comparison of BEAS 2B cell monolayers, human organ cultures, and Goettinger minipigs.
Radiation research 2003;160(6):647-54.
2003: Brigitte Mahnert; Stefan Tauber; Martin Kriegmair; Dorothea Nagel; Stefan Holdenrieder; Karin Hofmann; Wolfgang Reiter; Nikolaus Schmeller; Petra Stieber
Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
Clinical chemistry and laboratory medicine : CCLM / FESCC 2003;41(1):104-10.
2003: Thomas Muley; Werner Ebert; Petra Stieber; Hannelore Raith; Stefan Holdenrieder; Dorothea Nagel; Heinrich Fürst; Heinz-Jürgen Roth; Hilmar Luthe; Bert G Blijenberg; Eberhard Gurr; Wolfgang Uhl; Joachim von Pawel; Peter Drings
Technical performance and diagnostic utility of the new Elecsys neuron-specific enolase enzyme immunoassay.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2003;41(1):95-103.
2001: Stefan Holdenrieder; Petra Stieber; H Bodenmüller; M Busch; Joachim von Pawel; Andreas Schalhorn; Dorothea Nagel; Dietrich Seidel
Circulating nucleosomes in serum.
Annals of the New York Academy of Sciences 2001;945():93-102.
2001: Stefan Holdenrieder; Petra Stieber; H Bodenmüller; G Fertig; Heinrich Fürst; Nikolaus Schmeller; M Untch; Dietrich Seidel
Nucleosomes in serum as a marker for cell death.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2001;39(7):596-605.
2001: Stefan Holdenrieder; Petra Stieber; H Bodenmüller; M Busch; G Fertig; Heinrich Fürst; Andreas Schalhorn; Nikolaus Schmeller; M Untch; Dietrich Seidel
Nucleosomes in serum of patients with benign and malignant diseases.
International journal of cancer. Journal international du cancer 2001;95(2):114-20.
2000: Lubos Holubec; Ondrej Topolcan; Richard Pikner; Ladislav Pecen; J Vaclavickova; M Wirthova; J Molacek; Petra Stieber; Stefan Holdenrieder; L H Sen; Jindrich Finek
The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence.
Anticancer research 2000;20(6D):5237-44.
1999: Stefan Holdenrieder; Petra Stieber; T Förg; M Kühl; L Schulz; M Busch; Andreas Schalhorn; Dietrich Seidel
Apoptosis in serum of patients with solid tumours.
Anticancer research 1999;19(4A):2721-4.